LUCD — Lucid Diagnostics Inc.

Summary of Lucid Diagnostics Inc. (LUCD) Q3 2025 Earnings Call

1. Key Financial Results and Metrics

• Test Volume: 2,841 tests conducted in Q3 2025, consistent with the previous quarter.
• Revenue: Approximately $1.2 million recognized, reflecting a 4% sequential increase and a 3% year-over-year increase.
• Burn Rate: $10.3 million for the quarter, slightly better than the previous quarter's average of $10.5 million.
• Cash Position: $47.3 million at the end of Q3, bolstered by a public offering that raised approximately $27 million.
• Loss: Non-GAAP net loss of $10.3 million, with a loss per share of $0.10, consistent with previous quarters.

2. Strategic Updates and Business Highlights

• Medicare Coverage: Positive outcomes from the MolDx CAC meeting on September 4, 2025, with strong consensus among experts for EsoGuard Medicare coverage.
• Market Access Team: Strengthened leadership with experienced hires to enhance payer engagement and secure broader insurance coverage.
• Commercial Focus: Transitioning to target Medicare patients, aiming to capture a significant portion of the 30 million target population, which includes approximately 50% Medicare-eligible patients.
• Firefighter Summit: Upcoming event focused on esophageal cancer prevention, leveraging partnerships with fire departments to enhance community outreach and testing initiatives.

3. Forward Guidance and Outlook

• Medicare Draft LCD: Anticipation of a draft local coverage determination soon, with expectations that the transition from draft to final will be a formality.
• Commercial Payer Engagement: Increased activity and positive movement in discussions with commercial payers, with expectations of securing coverage policies ahead of Medicare approval.
• Long-term Growth: Plans to scale operations and increase test volume once Medicare coverage is secured, with a focus on maintaining fiscal discipline in the interim.

4. Bad News, Challenges, or Points of Concern

• Reimbursement Risks: Current reliance on Medicare approval, which impacts about 40% of the addressable patient population, poses a risk to future revenue recognition.
• Operational Burn: While the burn rate is stable, the company must navigate its financial resources carefully until Medicare coverage is secured.
• Market Competition: The need to establish a strong foothold in the market as competition increases, particularly in securing contracts with commercial payers.

5. Notable Q&A Insights

• Medicare Engagement: Management emphasized the importance of engaging Medicare patients now to maximize look-back revenue once coverage is secured.
• Commercial Payer Strategies: Positive feedback from commercial payers is being driven by the integration of EsoGuard into existing clinical guidelines, enhancing its acceptance.
• NIH Study: Ongoing studies with NIH and VA are expected to expand the potential market for EsoGuard, though results are not anticipated to impact immediate revenue.
• Physician Engagement: High compliance rates for patients referred for testing indicate strong physician engagement and the effectiveness of the EsoGuard test in clinical practice.

Overall, Lucid Diagnostics is positioned for potential growth, contingent on securing Medicare coverage, while actively enhancing its market presence and payer relationships.